AgrawalRGillieDMungenastA, et al. (2025) Zalsupindole is a nondissociative, nonhallucinogenic neuroplastogen with therapeutic effects comparable to ketamine and psychedelics. ACS Chem Neurosci16(22): 4388–4399.
2.
AllisonJHStewartMA. (1971) Reduced brain inositol in lithium-treated rats. Nat New Biol233(43): 267–268.
3.
AtackJRCookSMWattAP, et al. (1993) In vitro and in vivo inhibition of inositol monophosphatase by the bisphosphonate L-690,330. J Neurochem60(2): 652–658.
4.
AuwerxCKutalikZReymondA. (2024) The pleiotropic spectrum of proximal 16p11.2 CNVs. Am J Hum Genet111(11): 2309–2346.
5.
BrowningMCowenPJGalalU, et al. (2025) Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: A placebo-controlled, double-blind, randomised trial in the UK. Lancet Psychiatry12(8): 579–589. Erratum in: Lancet Psychiatry 12(9): e17.
6.
CotziasGCPapavasiliouPSGelleneR. (1969) Modification of Parkinsonism–chronic treatment with L-dopa. N Engl J Med280(7): 337–345.
7.
DongJBlierP (2001) Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl)155(1): 52–57.
8.
EgertonAShotboltJPStokesPR, et al. (2010) Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: An [11C]raclopride PET study. Neuroimage50(1): 260–266.
9.
GlenAIReadingHW (1973) Regulatory action of lithium in manic-depressive illness. Lancet2(7840): 1239–1241.
10.
GodfreyKDouglassHErritzoeD, et al. (2025) The role of GABA, glutamate, and Glx levels in treatment of major depressive disorder: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry141: 111455.
11.
GrotzingerADWermeJPeyrotWJ, et al. (2026) Mapping the genetic landscape across 14 psychiatric disorders. Nature649(8096): 406–415.
12.
HornykiewiczO. (1966) Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev18(2): 925–964.
13.
JoshiKRaoSMehtaS. (2025) A review of pharmacokinetic and pharmacodynamic properties of quetiapine IR and XR: Insights and clinical practice implications. Cureus17(6): e86258.
14.
KatzRIChaseTNKopinIJ. (1968) Evoked release of norepinephrine and serotonin from brain slices: Inhibitoon by lithium. Science162(3852): 466–467.
15.
KvamT-MGoksøyrIWRogJ, et al. (2025) MDMA-assisted therapy as a treatment for major depressive disorder: Proof of principle study. Br J Psychiatry227(5): 783–789.
16.
MillanMJ (2014) On ’polypharmacy’ and multi-target agents, complementary strategies for improving the treatment of depression: A comparative appraisal. Int J Neuropsychopharmacol17(7): 1009–1037.
17.
MitchellJMBogenschutzMLiliensteinA, et al. (2021) MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nat Med27(6): 1025–1033.
18.
MoraruMVStoleruSZugravuA, et al. (2024) New insights into pharmacology of GABAA receptor alpha subunits-selective modulators. Am J Ther31(6): e669–e676.
19.
NardouRSawyerESongYJ, et al. (2023) Psychedelics reopen the social reward learning critical period. Nature618(7966): 790–798.
20.
NuttDJ (2025) Drug development in psychiatry: 50 years of failure and how to resuscitate it. Lancet Psychiatry12(3): 228–238.
21.
NuttD (2014) Help luck along to find psychiatric medicines. Nature515: 165.
22.
NuttDJGleiterCHGlueP (1989) Neuropharmacological aspects of ECT: In search of the primary mechanism of action. Convuls Ther5(3): 250–260.
23.
NuttDJStahlSM (2010) Searching for perfect sleep: The continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol24(11): 1601–1612.
24.
PehrsonALSanchezC (2014) Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr19(2): 121–133.
25.
PellegriniLFinebergNAO’ConnorS, et al. (2025) Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study. Compr Psychiatry142: 152619.
26.
RochCBergaminiGSteinerMA, et al. (2021) Nonclinical pharmacology of daridorexant: A new dual orexin receptor antagonist for the treatment of insomnia. Psychopharmacology (Berl)238(10): 2693–2708.
27.
RouxSSabléEPorsoltRD (2005) Primary observation (Irwin) test in rodents for assessing acute toxicity of a test agent and its effects on behavior and physiological function. Curr Protoc Pharmacol10: 10.10.
28.
SmithDDempsterCGlanvilleJ, et al. (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis. Br J Psychiatry180(5): 396–404.
29.
SnitowMEBhansaliRSKleinPS. (2021) Lithium and therapeutic targeting of GSK-3. Cells10(2): 255.
30.
Socoró-GarrigosaMPerlYSKringelbachML, et al. (2025) Perturbing whole-brain models of brain hierarchy: An application for depression following pharmacological treatment. Ann N Y Acad Sci1550(1): 255–272.
31.
StambolicVRuelLWoodgettJR (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol6(12): 1664–1668.
32.
UlrichSRickenRAdliM (2017) Tranylcypromine in mind (Part I): Review of pharmacology. Eur Neuropsychopharmacol27(8): 697–713.
33.
van BruggenFMcIntyreRS (2026) Development of major depressive disorder-does insulin resistance play a role?JAMA Psychiatry83: 428.
34.
WilsonSHøjerAMBuchbergJ, et al. (2015) Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. J Psychopharmacol29(10): 1085–1091.
35.
WilliamsKSmithJGlueP, et al. (1992) The effects of electroconvulsive therapy on plasma insulin and glucose in depression. Br J Psychiatry161: 94–98.
36.
WagstaffAJTacrineMD (1994) A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer’s disease. Drugs Aging4(6): 510–540.
